ArticleClinical pharmacology and therapeutics2017
Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity.
Article in Clinical pharmacology and therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.Medical oncology (Northwood, London, England) · 2021Trial
- Platinum accumulation in chemotherapy: toxicity mechanisms, challenges, and mitigation strategies.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Review
- Oxidative Stress-Driven Mechanisms and Biomarkers of Drug-Induced Nephrotoxicity: Translational Insights and Therapeutic Implications.Antioxidants (Basel, Switzerland) · 2026Review
- Special Issue: "Pharmacological Strategies and Molecular Mechanisms Associated with the Novel Nephroprotective Treatments".International journal of molecular sciences · 2025Article
- Biomarkers for Early Detection of Cisplatin-Induced Nephrotoxicity.Life (Basel, Switzerland) · 2025Article
- Bardoxolone methyl improves survival and reduces clinical measures of kidney injury in tumor-bearing mice treated with cisplatin.AAPS open · 2025Article
- Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury.The Journal of pharmacology and experimental therapeutics · 2024Review
- New Markers of Early Kidney Damage in Children and Adolescents with Simple Obesity.International journal of molecular sciences · 2024Article
- Biomarkers in Contrast-Induced Acute Kidney Injury: Towards A New Perspective.International journal of molecular sciences · 2024Review
- The Value of Urinary NGAL, KIM-1, and IL-18 Measurements in the Early Detection of Kidney Injury in Oncologic Patients Treated with Cisplatin-Based Chemotherapy.International journal of molecular sciences · 2024Article
- Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches.Frontiers in nephrology · 2024Review
- A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule-1 Biomarker.Journal of pharmacology & clinical toxicology · 2024Article
- Potential Biomarkers for the Earlier Diagnosis of Kidney and Liver Damage in Acute Intermittent Porphyria.Life (Basel, Switzerland) · 2023Article
- The renal damage and mechanisms relevant to antitumoral drugs.Frontiers in oncology · 2023Review
- Regulation of renal calbindin expression during cisplatin-induced kidney injury.Journal of biochemical and molecular toxicology · 2022Article
- Derivation and validation of urinary TIMP-1 for the prediction of acute kidney injury and mortality in critically ill children.Journal of translational medicine · 2022Article
- Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury.Kidney360 · 2022Article
- Diagnostic Value of Multiple Serum Biomarkers for Vancomycin-Induced Kidney Injury.Journal of clinical medicine · 2021Article
- Urinary Exosomes Identify Inflammatory Pathways in Vancomycin Associated Acute Kidney Injury.International journal of molecular sciences · 2021Article
- Rational selection of a biomarker panel targeting unmet clinical needs in kidney injury.Clinical proteomics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
The success of cisplatin-containing regimens to treat solid tumors is limited, in part, by nephrotoxicity. In rodents, several urinary proteins have emerged that are sensitive indicators of cisplatin-induced kidney injury. We sought to characterize time-dependent changes in the urinary concentrations of 12 proteins, including kidney injury molecule-1 (KIM-1), calbindin, beta 2-microglobulin (β2M), and trefoil factor 3 (TFF3) after cisplatin therapy. Urine was collected at baseline, 3 days (range, 2-5 days), and 10 days (range, 9-11 days) from 57 patients with solid tumors receiving outpatient cisplatin therapy (≥25 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.